Chatting with Rachel Haurwitz, CEO, Caribou Bio
Rachel Haurwitz, CEO, Caribou Bio, discusses Caribou's technology for gene editing with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event.
Rachel Haurwitz, CEO, Caribou Bio, discusses Caribou's technology for gene editing with Pharm Exec's European Editor, Julian Upton, at the 2019 17th Annual Patient Engagement eyeforpharma Barcelona event.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
New Insights Into T Cell Exhaustion and Inflammation in Long COVID
April 17th 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and evidence of T cell exhaustion in long COVID patients, providing deeper insight into post-infection immune disruption.
